■碱性磷酸酶(ALP)在一定程度上反映了多发性骨髓瘤(MM)患者病情的变化。然而,MM中ALP的关系仍不确定。我们的研究旨在确定新诊断的MM患者的初始ALP水平与总体生存率之间的关系。
■收集2012-2016年北京朝阳医院202例新诊断MM患者的临床资料。基线特征,疾病进展分期,血清标记物,并记录患者生存数据.ALP的截止值是根据患者生存数据计算的,并将患者分组。患者3年和5年生存率的差异,肝功能,比较各组间骨病等指标。采用COX回归分析确定影响初诊MM患者的独立危险因素。
■根据ALP截止点将患者分为三组:第1组(ALP<70U/L),第2组(ALP70至<120U/L),和第3组(ALP≥120U/L)。在乳酸脱氢酶中观察到显着差异,血清钙,白细胞计数,血红蛋白,和肝功能指标(包括丙氨酸转氨酶,天冬氨酸转氨酶,白蛋白,和γ-谷氨酰转移酶)在不同ALP组之间(P<0.05)。不同骨病分级患者ALP水平差异有统计学意义(P<0.05)。第1、2和3组的中位生存时间分别为25、52和31个月。分别。第2组的3年生存率明显高于其他两组(P=0.006)。3组5年生存率差异无统计学意义(P=0.51)。年龄,国际分期系统分期,天冬氨酸转氨酶,β2-微球蛋白,ALP分级,严重骨病是影响初诊患者生存的独立因素(P<0.05)。
■ALP水平与MM患者的预后相关,ALP范围为70至<120U/L反映了更好的生存预期。
UNASSIGNED: Alkaline phosphatase (ALP) reflects changes in the condition of multiple myeloma (MM) patients to some extent. However, the relationship of ALP in MM remains uncertain. Our study aimed to determine the association between initial ALP levels and overall survival in newly diagnosed MM patients.
UNASSIGNED: Clinical data from 202 newly diagnosed MM patients at Beijing Chaoyang Hospital between 2012 and 2016 were collected. Baseline characteristics, disease progression staging, serum markers, and patient survival data were recorded. The cut-off value for ALP was calculated based on patient survival data, and patients were divided into groups. Differences in patients\' 3- and 5-year survival rates, liver function, bone disease and other indicators among different groups were compared. Independent risk factors influencing newly diagnosed MM patients were identified using COX regression analysis.
UNASSIGNED: Patients were categorized into three groups based on ALP cut-off points: Group 1 (ALP <70 U/L), Group 2 (ALP 70 to <120 U/L), and Group 3 (ALP ≥120 U/L). Significant differences were observed in lactate dehydrogenase, serum calcium, white blood cell count, hemoglobin, and liver function indicators (including alanine aminotransferase, aspartate aminotransferase, albumin, and γ-glutamyl transferase) among different ALP groups (P<0.05). ALP levels varied significantly among patients with different bone disease grades (P<0.05). Median survival times for Groups 1, 2, and 3 were 25, 52, and 31 months, respectively. Group 2 exhibited significantly higher 3-year survival compared to the other two groups (P=0.006), while no significant difference was observed in 5-year survival among the three groups (P=0.51). Age, International Staging System staging, aspartate aminotransferase, β2-microglobulin, ALP grading, and severe bone disease were identified as independent factors influencing survival in newly diagnosed patients (P<0.05).
UNASSIGNED: ALP levels are correlated with the prognosis of MM patients, and an ALP range of 70 to <120 U/L reflects a better survival expectation.